Coca-Cola Consolidated, Inc.
Coca-Cola Consolidated, Inc. (COKE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
coke · stock forecast · 1 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 1 Wall Street analysts in the past 3 months
Hold
1 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $176.74
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $178.36 | ↑ 0.92% |
1-day model range: $177.16–$179.55. Peak: $179.55 (+0.92%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $283 | +60.0% |
| 2028 | $393 | +122.4% |
| 2029 | $493 | +178.8% |
| 2030 | $574 | +224.7% |
| 2031 | — | +259.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · COKE · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2016-05-20 | Citigroup | Maintains | Neutral→Neutral |
| 2015-07-27 | Citigroup | Maintains | Neutral→Neutral |
| 2015-05-07 | Citigroup | Maintains | Neutral→Neutral |
| 2015-03-06 | Citigroup | Maintains | Neutral→Neutral |
| 2014-11-13 | Citigroup | Maintains | Neutral→Neutral |
| 2014-08-08 | Citigroup | Maintains | Neutral→Neutral |
| 2012-08-08 | Citigroup | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Coca-Cola Consolidated, Inc. (COKE) stock. Of the recent 7 rating actions, 0 were upgrades and 0 were downgrades. 1 analysts currently cover COKE.
Analyst Recommendation Trends
COKE analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$5.5B
↓ 10.3% YoY
Revenue Next Year
$5.9B
↑ 8.5% YoY
EPS This Year
$3.30
EPS Next Year
$3.67
↑ 11.0% YoY
EPS ForecastReported vs Estimated
Analysts forecast COKE EPS of $3.30 for the current fiscal year, based on estimates from 5 analysts. The COKE revenue forecast is $5.5B for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The COKE stock forecast is supported by two independent data sources: analyst consensus ratings from 1 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus COKE price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The COKE short-term stock prediction for tomorrow is $178.36 (+0.92%). The COKE stock price prediction for 2027 estimates an average of $283. The COKE stock prediction for 2030 projects a range of $532–$616.
Coca-Cola Consolidated, Inc. trades on NASDAQ under the ticker COKE. The COKE stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 0% of covering analysts.
Frequently asked questions
COKE forecast · 8 questionsAccording to 1 Wall Street analysts, the average 12-month COKE price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $176.74.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.